Friday, July 3, 2009
Surviving the storm: how to stay afloat in troubled financial waters. Plus the latest on Lean, and the challenges of setting up international clinical trials.
Sponsors
Platinum Sponsors
Editor’s Blog
Where our team of editors discuss what they think about the current NGP US Issues.
Marie Shields
Editor NGP Europe
Editor NGP Europe
Stormy weather
The pharmaceutical industry has been having a bit of a bumpy ride lately. Mergers, layoffs, cost-cutting exercises – it seems we are not immune to the stormy effects of the global financial crisis after all.09 Apr 2009
No Comments
Editor’s Choice
-
Patient power
Millennium’s Isabelle Mercier tells NGP about the rising power of patient influence and marketing’s delivery of information demand.Read more -
Cut down, collaborate and focus on the customer
Pfizer’s Kim Sendall lets NGP in on his vision for the manufacturing facility of the future.Read more -
New concepts in risk control
Bayer’s Helmut Mothes examines the success of Lean and the development of operational excellence.Read more -
Slim down, tone up
Realigning from the company from within to keep up with the ever-changing vitality of pharma manufacturing has been no mean feat for Novartis’ Steve Dreamer.Read more -
Pest control
Protecting the public and pharmaceutical companies from counterfeit drugs is all in a day’s work for the MHRA’s Mick Deats.Read more -
The genetic advantage
Allen Roses tells NGP how pharmacogenetics can help cut the size and cost of clinical trials.Read more
Readers’ Choice
-
Process excellence in master data manage...
It makes sense to analyze and ensure that the foundations of master data governance are solid and provide the business with strong processes to manage and share master data...Read more -
End-to-end clinical trials supply manage...
Stakeholders point to the clinical costs as a barrier to innovation. The FDA has confirmed in its “Critical path report” that “Streamlining Clinical Trials” is one of the key...Read more -
Imaging is key to success in oncology tr...
As defined by the NCI, "Translational research transforms scientific discoveries arising from laboratory, clinical, or population studies into clinical applications to reduce...Read more -
Emerging importance of health economics ...
Jacco Keja, Managing Director and Practice Leader at Quintiles Consulting, Visiting Professor Life Sciences Pricing, Erasmus University, looks at the emerging opportunities for...Read more -
Building a sustainable biotech business ...
By Willem van Leeuwen – Managing Director QMR TechnologyRead more -
Drive your innovation towards smarter re...
Ever-faster innovation. Ever-stronger competition from generics. And more and more people involved in the purchasing decision.Read more
Search
Quick Vote
How will the recession affect the European pharmaceutical industry?
Executive Interviews
Tools for screening and validation
Taqman SNP Genotyping Assays, developed by Applied Biosystems, are a state-of-the-art technology for screening and validation of polymorphisms. Recently Applied Biosystems introduced two new products to complement this offering; the high throughpu...
Read more
The future of drug repositioning
Andreas Persidis of Biovista talks to NGP about the transformational potential of drug repositioning.
Read more
NGP Europe Summit 2009
15th - 17th September
The Pharmaceutical and Biopharmaceutical industry has the challenge of finding more innovative ways to get products to market more effectively and profitably.
Source: www.ngpharma.eu.com© 2009 GDS Publishing Ltd. All rights reserved.